Entropy Neurodynamics (ENP.AX) Stock Price

Entropy Neurodynamics Price

ASX·CLOSED
0.03
​
Market closed

Revenue has compounded at 151.6% per year over the past 3 years to 1.59 M AUD. Entropy Neurodynamics's net margin stands at -335.9%, up from -10,111.3% several years earlier.

Entropy Neurodynamics stock price

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Entropy Neurodynamics business model & stock analysis

Entropy Neurodynamics Ltd develops and commercializes exosomes as therapeutic agents. The company holds intellectual property related to exosome technology and offers LEAP manufacturing, LOAD API loading, and EVPS tropism technologies. Pharmaceutical and biotechnology companies purchase these proprietary technologies to enhance their own exosome-based products. The firm invests in biopharmaceutical drug development and leverages its portfolio of know-how to support partners in exosome medicine development. Exopharm Ltd. is the company's brand name, and it operates through its exosome technology portfolio. The firm's technologies solve key challenges in exosome medicine success, including manufacturing efficiency and targeted delivery. Biopharmaceutical companies are the primary buyers of these technologies, seeking to integrate exosome delivery systems into their therapeutic pipelines. The company's business model centers on licensing its exosome-related IP and know-how to pharmaceutical and biotech firms. By providing LEAP, LOAD API, and EVPS technologies, Entropy Neurodynamics enables partners to overcome technical barriers in exosome-based drug development. This approach generates revenue through technology licensing agreements with industry partners.

Frequently asked questions about Entropy Neurodynamics

7 analysts currently rate the Entropy Neurodynamics stock: 0 recommend buying, 3 holding and 4 selling.

Converted at the current exchange rate, the Entropy Neurodynamics share trades at 0.02 EUR (0.03 AUD).

The Entropy Neurodynamics share (ENP.AX) is listed on 1 stock exchanges, including: ASX (EX1.AX).

The revenue cannot currently be calculated for Entropy Neurodynamics.

The profit of Entropy Neurodynamics is -4.87 M AUD. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of Entropy Neurodynamics is currently -8.98. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Entropy Neurodynamics stock.

The P/S cannot be calculated for Entropy Neurodynamics currently.

The Eulerpool Quality Score for Entropy Neurodynamics is 3/10.

The ISIN of Entropy Neurodynamics is AU0000433583. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The ticker of Entropy Neurodynamics is ENP.AX. The ticker symbol is used to trade Entropy Neurodynamics shares on the stock exchange.

Fair ValueTerminal
0.02 AUD
Over-/UndervaluationTerminal
Fairly valued
Sector
Industry
Biotechnology
Number of shares
Employees
Revenue growth Ø5 years
EBIT growth Ø5 years
Net Income growth Ø5 years
Website exopharm.com
Country
Australia
Currency
AUD
Initial public offering
Dec 18, 2018
ISIN
AU0000433583
Cusip
Q3658N100
Market capitalization
40.67 M AUDMicro Cap
52-Week Range
PEG
—
P/E ratio
P/Ee
—
P/Se
—
EV/EBIT
—
P/B Ratio
5.52
ROE (Return on Equity)
ROA (Return on Assets)
ROCE (Return on Capital Employed)
ROIC (Return on Invested Capital)
-66.12 %
Last updated Nov 22, 2026, 3:46 AM

Entropy Neurodynamics Peer Group

Entropy Neurodynamics Ticker

ASX · EX1.AX